Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 4/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.34 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3629208 | 0.89 | RAF1 (0.43) | RAF1MAPK13MAPK14 | |
| SCHEMBL7813599 | 0.78 | MAPK13 (0.48) | RAF1MAPK13MAPK14 | |
| SCHEMBL6049566 | 0.76 | MAPK14 (0.43) | RAF1MAPK14 | |
| SCHEMBL6049496 | 0.76 | MAPK14 (0.43) | MAPK13MAPK14 | |
| SCHEMBL6049499 | 0.71 | PTK2 (0.34) | — | |
| SCHEMBL667815 | 0.69 | RAF1 (0.60) | RAF1MAPK13MAPK14 | |
| SCHEMBL9894387 | 0.69 | MAPK14 (0.38) | RAF1MAPK14 | |
| SCHEMBL27564998 | 0.69 | CCNA2 (0.42) | HSD17B1HSD17B2 | |
| SCHEMBL7810441 | 0.67 | MAPK13 (0.54) | RAF1MAPK13MAPK14 | |
| SCHEMBL6049567 | 0.66 | RAF1 (0.38) | RAF1MAPK13MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4403482-B2 | — | — | 2010-01-27 | — | — | JP | claimed |
| EP-1041982-A4 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2006-06-14 | — | — | EP | claimed |
| JP-2001526223-A | — | — | 2001-12-18 | — | — | JP | claimed |
| EP-1041982-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-10-11 | — | — | EP | claimed |
| WO-1999032111-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | claimed |
| EP-1041982-A4 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1041982-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032111-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |